FDA OKs Guardant Health liquid biopsy test for tumor mutation profiling

The FDA approves Guardant Health’s (GH +4.2%) Guardant360 Dx for tumor mutation profiling in patients with any solid malignant tumor.

Previously, the liquid biopsy test was approved as a companion diagnostic for AstraZeneca’s (AZN -1.7%) Tagrisso (osimertinib).

https://seekingalpha.com/news/3603007-fda-oks-guardant-health-liquid-biopsy-test-for-tumor-mutation-profiling